UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients with Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

Participants in this research study have been diagnosed with cancer that has progressed or not responded to prior treatments containing rituximab. The purpose of this research study is to compare the effects, good and/or bad, of the experimental drug GA101 given in combination with bendamustine compared with bendamustine alone, to find which treatment is better. Approximately 360 people will take part in this study at about 80-120 study centers in the United States and other countries.

Start Date
September 2, 2010
End Date
September 2, 2020
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Brian Link, MD
Contact Info

Mary Schall, 319-356-9516

bendamustine ; cancer ; GA101 ; IRB#201001555 ; link ; phase 3 ; phase III ; rituximab ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.